Time to act for a better management of dyslipidemia in patients with multiple cardiovascular risk Dyslipidemia View all Contents Time to act for a better management of dyslipidemia in patients with multiple cardiovascular risk You can now watch the recording of the "Time to act for a better management of dyslipidemia in patients with multiple cardiovascular risk” live webinar, related to the educational program “Deep Dive into Dyslipidemia: myths & realities”.
Q&A session: Choosing the best treatment approach to dyslipidemia: monotherapy vs combination therapy Dyslipidemia View all Contents Q&A session: Choosing the best treatment approach to dyslipidemia: monotherapy vs combination therapy An open discussion with A. Zambon and L. Perez de Isla on questions submitted by the audience at ESC 2020.
Feedback on patients treated with highly intensity statin/ezetimibe combinations. Do we need to go further? Dyslipidemia View all Contents Feedback on patients treated with highly intensity statin/ezetimibe combinations. Do we need to go further? Alberto Zambon and Leopoldo Perez de Isla conduct a concise analysis about choices around monotherapy and combination therapy in dyslipidemia.
How have the French and Spanish (local) Cardiology Societies interpreted the ESC Guidelines? Insights and recommendations. Dyslipidemia View all Contents How have the French and Spanish (local) Cardiology Societies interpreted the ESC Guidelines? Insights and recommendations. Leopoldo Perez de Isla discusses 2 interesting approaches to the updated version of ESC guidelines.
What is the key evidence supporting LDL-C control at lower targets, with earlier intervention for better outcomes in the long-term? Dyslipidemia View all Contents What is the key evidence supporting LDL-C control at lower targets, with earlier intervention for better outcomes in the long-term? Interesting evidence by Dr. Pérez de Isla on lowering LDL-C, focused on 3 main aspects: Get it low – Get it soon – Get it forever.
